This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Aceglutamide
An acetylated form of L-glutamine (N-acetyl-L-glutamine) with enhanced blood-brain barrier penetration, used in Asia as a nootropic and neuroprotectant for cerebrovascular disorders.
Benefits
What is Aceglutamide?
Aceglutamide (N-acetyl-L-glutamine) is an acetylated derivative of the amino acid L-glutamine that was developed to improve the delivery of glutamine to the central nervous system. By adding an acetyl group to the glutamine molecule, Aceglutamide achieves significantly greater blood-brain barrier permeability compared to unmodified L-glutamine, allowing for more efficient CNS penetration and higher brain concentrations at lower oral doses. The compound has been marketed and prescribed in several Asian countries, particularly Japan and China, for the treatment of cerebrovascular disorders, post-stroke recovery, and cognitive impairment associated with cerebral insufficiency. In these markets, it is available in both oral and injectable forms, often under names like Aceglutamide Aluminum (when formulated as an aluminum salt complex) for injection.
The pharmacological rationale for Aceglutamide lies in its role as a precursor to both glutamate and GABA, the brain's primary excitatory and inhibitory neurotransmitters respectively. Once in the brain, Aceglutamide is deacetylated to L-glutamine, which is then converted to glutamate by the enzyme glutaminase. Glutamate can subsequently be converted to GABA by glutamic acid decarboxylase (GAD). This dual precursor role allows Aceglutamide to support both excitatory (learning, memory, synaptic plasticity) and inhibitory (anxiety reduction, neuroprotection) neurotransmission. Clinical studies in Japanese and Chinese medical literature have documented improvements in cognitive function, cerebral blood flow, and neurological outcomes in patients with cerebrovascular disease. Research by Ogawa (1976) and subsequent Japanese clinical studies demonstrated that Aceglutamide improved performance on cognitive assessment batteries and enhanced EEG patterns associated with alertness and cognitive processing in elderly patients with cerebral arteriosclerosis.
- Enhanced BBB penetration: The N-acetyl modification significantly improves blood-brain barrier permeability compared to unmodified L-glutamine, allowing higher CNS bioavailability at lower systemic doses
- Glutamate precursor: Deacetylated in the brain to L-glutamine, which is subsequently converted to glutamate by glutaminase, supporting excitatory neurotransmission essential for learning, memory, and synaptic plasticity
- GABA precursor: Through the glutamate-GABA metabolic pathway (via glutamic acid decarboxylase), serves as an indirect precursor to GABA, supporting inhibitory neurotransmission and neuroprotection
- Cerebral energy metabolism: L-glutamine participates in the glutamate-glutamine cycle between neurons and astrocytes, supporting cerebral energy metabolism and ammonia detoxification in the brain
- Neuroprotective effects: May protect against ischaemic brain damage by maintaining neurotransmitter balance and supporting cellular energy metabolism during periods of reduced cerebral blood flow
- Oral dosage: 100-300 mg taken two to three times daily (total daily dose of 200-900 mg) in clinical settings in Japan and China
- Injectable form: Aceglutamide Aluminum injection is administered at 100-200 mg via intramuscular or slow intravenous injection in hospital settings for acute cerebrovascular conditions
- Duration of treatment: Oral treatment courses typically last 4-12 weeks, with some protocols extending to several months for chronic cerebrovascular conditions
- Administration: Oral tablets or capsules taken with meals; the injectable form is reserved for clinical settings under medical supervision
- Availability: Primarily available in Japan, China, and some other Asian countries; not approved by the FDA or EMA, though the compound can be sourced from research chemical suppliers
- Generally well-tolerated: Clinical experience in Asian markets has shown a favourable safety profile, with most adverse effects being mild gastrointestinal complaints including nausea, abdominal discomfort, and diarrhoea
- Aluminum concerns (injectable form): The Aceglutamide Aluminum formulation carries theoretical concerns about aluminum accumulation, particularly with long-term use or in patients with renal impairment
- Glutamate sensitivity: As a glutamate precursor, caution is warranted in individuals sensitive to glutamate or those with conditions exacerbated by excitatory neurotransmission (e.g., epilepsy)
- Renal impairment: Dose adjustment may be necessary in patients with significant renal dysfunction, particularly for the aluminum-containing formulation
- Limited Western safety data: Most safety information comes from Japanese and Chinese post-marketing surveillance, which may not meet Western regulatory standards for comprehensive pharmacovigilance
Natural Sources & Forms
- Ogawa (1976): Clinical study on Aceglutamide's effects on cognitive function in patients with cerebral arteriosclerosis, published in Japanese Journal of Pharmacology
- Japanese pharmaceutical registry: Product monograph and prescribing information for Aceglutamide tablets and Aceglutamide Aluminum injection as approved in Japan
- Chinese pharmacopoeia: Monograph on Aceglutamide Aluminum injection including quality standards, clinical indications, and dosing guidelines
- Glutamine metabolism review: Albrecht et al. (2010) - "Glutamine in the central nervous system" reviewing the role of glutamine and its derivatives in brain function and pathology
- Blood-brain barrier transport: Gynther et al. (2008) - review of amino acid prodrug strategies for CNS delivery, including N-acetylation approaches exemplified by Aceglutamide
Frequently Asked Questions
An acetylated form of L-glutamine (N-acetyl-L-glutamine) with enhanced blood-brain barrier penetration, used in Asia as a nootropic and neuroprotectant for cerebrovascular disorders.
The key benefits of Aceglutamide include: Anxiety & Calm, Cognitive Enhancement, Focus, Longevity, Memory, Mood.
Enhanced BBB penetration: The N-acetyl modification significantly improves blood-brain barrier permeability compared to unmodified L-glutamine, allowing higher CNS bioavailability at lower systemic doses Glutamate precursor: Deacetylated in the brain to L-glutamine, which is subsequently converted to glutamate by glutaminase, supporting excitatory neurotransmission essential for learning, memory, and synaptic plasticity GABA precursor: Through the glutamate-GABA metabolic pathway (via glutamic acid decarboxylase), serves as an indirect precursor to GABA, supporting inhibitory neurotransmission and neuroprotection Cerebral energy metabolism: L-glutamine participates in the glutamate-glutamine cycle between neurons and astrocytes, supporting cerebral energy metabolism and ammonia detoxification in the brain Neuroprotective effects: May protect against ischaemic brain damage by maintaining neurotransmitter balance and supporting cellular energy metabolism during periods of reduced cerebral blood flow
Oral dosage: 100-300 mg taken two to three times daily (total daily dose of 200-900 mg) in clinical settings in Japan and China Injectable form: Aceglutamide Aluminum injection is administered at 100-200 mg via intramuscular or slow intravenous injection in hospital settings for acute cerebrovascular conditions Duration of treatment: Oral treatment courses typically last 4-12 weeks, with some protocols extending to several months for chronic cerebrovascular conditions Administration: Oral tablets or capsules taken with meals; the injectable form is reserved for clinical settings under medical supervision Availability: Primarily available in Japan, China, and some other Asian countries; not approved by the FDA or EMA, though the compound can be sourced from research chemical suppliers
Generally well-tolerated: Clinical experience in Asian markets has shown a favourable safety profile, with most adverse effects being mild gastrointestinal complaints including nausea, abdominal discomfort, and diarrhoea Aluminum concerns (injectable form): The Aceglutamide Aluminum formulation carries theoretical concerns about aluminum accumulation, particularly with long-term use or in patients with renal impairment Glutamate sensitivity: As a glutamate precursor, caution is warranted in individuals sensitive to glutamate or those with conditions exacerbated by excitatory neurotransmission (e.g., epilepsy) Renal impairment: Dose adjustment may be necessary in patients with significant renal dysfunction, particularly for the aluminum-containing formulation Limited Western safety data: Most safety information comes from Japanese and Chinese post-marketing surveillance, which may not meet Western regulatory standards for comprehensive pharmacovigilance
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!